Melanoma
Conference Coverage
Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19
The mortality rate was 8% among patients who received immune checkpoint inhibitors, which is comparable with the overall mortality rate among...
From the Journals
Hepatitis screening now for all patients with cancer on therapy
All patients with cancer who are candidates for systemic therapy should be screened for hepatitis B, says the American Society of Clinical...
Feature
ASCO says ‘no’ to home infusions of cancer treatment, with exceptions
The American Society of Clinical Oncology has warned against intravenous infusion of chemotherapy and monoclonal antibodies in cancer patients’...
From the Journals
OK to treat many cancer patients despite pandemic, says ESMO
ESMO recommends against stopping or delaying cancer treatment that can impact survival.
News from the FDA/CDC
FDA approves triple drug combo for melanoma
Conference Coverage
Memphis clinic created to care for children and adolescents diagnosed with melanoma
To date, 20 female and 18 male patients have traveled to the clinic from 21 states and Puerto Rico for assessment and consultation.
Conference Coverage
CCC19, other registries help define COVID/cancer landscape
New data from CCC19 show an increased risk of death from COVID-19 among non-Hispanic black cancer patients and patients with hematologic...
Clinical Insights
How aging affects melanoma development and treatment response
Conference Coverage
Real-world data support adjuvant immunotherapy for stage III melanoma
Immunotherapy after surgery for stage III melanoma conferred survival advantages in a real-world population.
News from the FDA/CDC
FDA approves new indications for pembrolizumab
Conference Coverage
Personalized cancer vaccine may enhance checkpoint inhibitor activity